FTC Sepracor Inquiry Suggests New Antitrust Thrust: Evergreen Deals

The Federal Trade Commission review of the Lilly/Sepracor agreement to develop (R)-fluoxetine suggests that FTC's interest in potential anti-generic strategies is expanding beyond abuse of process into corporate liaisons and development deals.